Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Bone-modifying agents as adjuvant therapy for early-stage breast cancer.

Figueroa-Magalhães MC, Miller RS.

Oncology (Williston Park). 2012 Oct;26(10):955-62. Review.

2.

Denosumab and the current status of bone-modifying drugs in breast cancer.

Lee BL, Higgins MJ, Goss PE.

Acta Oncol. 2012 Feb;51(2):157-67. doi: 10.3109/0284186X.2011.633555. Epub 2011 Dec 12. Review.

PMID:
22150116
3.

Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

Lipton A.

Breast Cancer Res Treat. 2010 Aug;122(3):627-36. doi: 10.1007/s10549-010-0935-7. Epub 2010 May 21. Review.

PMID:
20490653
4.

Prevention of bone metastases and management of bone health in early breast cancer.

Gnant M, Hadji P.

Breast Cancer Res. 2010;12(6):216. doi: 10.1186/bcr2768. Epub 2010 Dec 17. Review.

5.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
6.

Anticancer activity of bisphosphonates in breast cancer.

Gnant M.

Anticancer Agents Med Chem. 2012 Feb;12(2):114-22. Review.

PMID:
21864231
7.

[The role of bisphosphonates of adjuvant therapy in breast cancer].

Gálvez-Muñoz E, Rodríguez-Lescure Á.

Med Clin (Barc). 2010 Jun 12;135(2):70-4. doi: 10.1016/j.medcli.2009.10.013. Review. Spanish.

PMID:
20022069
8.

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?

Freedman OC, Amir E, Clemons MJ.

Crit Rev Oncol Hematol. 2009 Oct;72(1):56-64. doi: 10.1016/j.critrevonc.2009.03.001. Epub 2009 Mar 23. Review.

PMID:
19307138
9.

Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.

Li J, Rugo HS.

Breast Dis. 2011;33(2):83-92. doi: 10.3233/BD-2010-0326. Review.

PMID:
22142661
10.

Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer.

Coleman R.

Clin Breast Cancer. 2007 Jul;7 Suppl 1:S29-35. Review.

PMID:
17683651
11.

Bisphosphonates and breast cancer incidence and recurrence.

Chlebowski RT, Col N.

Breast Dis. 2011;33(2):93-101. doi: 10.3233/BD-2010-0324. Review.

PMID:
22142660
12.

Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.

Gnant M.

Curr Cancer Drug Targets. 2009 Nov;9(7):824-33. Review.

PMID:
20025570
13.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I.

Ann Oncol. 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Review.

PMID:
26681681
14.

The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.

Paterson AH.

Cancer. 2000 Jun 15;88(12 Suppl):3038-46. Review.

PMID:
10898349
15.

The role of bisphosphonates in early breast cancer.

Paterson AH.

Oncologist. 2006;11 Suppl 1:13-9. Review.

16.

Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.

Coleman RE.

Curr Opin Support Palliat Care. 2012 Sep;6(3):322-9. doi: 10.1097/SPC.0b013e32835689cd. Review.

PMID:
22801464
17.

Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy.

Kohno N, Kokufu I.

Breast Cancer. 2003;10(1):33-7. Review.

PMID:
12525761
18.

New results from the use of bisphosphonates in cancer patients.

Coleman R, Gnant M.

Curr Opin Support Palliat Care. 2009 Sep;3(3):213-8. doi: 10.1097/SPC.0b013e32832f4149. Review.

PMID:
19561507
19.

Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.

Gnant M.

Breast Dis. 2011;33(2):71-81. doi: 10.3233/BD-2010-0325. Review.

PMID:
22142663
20.

Should oral bisphosphonates be standard of care in women with early breast cancer?

Clemons M, Verma S.

Breast Cancer Res Treat. 2005 Apr;90(3):315-8. Review.

PMID:
15830146

Supplemental Content

Support Center